Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer

International Journal of Urology

Volumn 21, Issue 1, 2014, Pages 3-4

  Ohyama, Chikara ^a   Hatakeyama, Shingo ^a   Yoneyama, Takahiro ^a   Koie, Takuya ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; JAPAN; KIDNEY FUNCTION; LYMPH NODE DISSECTION; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84891559201     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12230     Document Type: Article

References (10)

1. Stein JP, Lieskovsky G, Cote R etal. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 2001; 19: 666-675.
2. Gore JL, Litwin MS, Lai J etal. Use of radical cystectomy for patients with invasive bladder cancer. J. Natl. Cancer Inst. 2010; 102: 802-811.
3. Grossman HB, Natale RB, Tangen CM etal. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 859-866.
4. International Collaboration of Trial on behalf of the Medical Research Council Advanced Bladder Cancer Working Party. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 2011; 29: 2171-2177.
5. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 2007; 178: 451-454.
6. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009; 115: 988-996.
7. Nicholson S. Chemotherapy for bladder cancer in patients with impaired renal function. Nat. Rev. Urol. 2011; 9: 52-57.
8. Koie T, Ohyama C, Hashimoto Y etal. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int. J. Clin. Oncol. 2012; doi: 10.1007/s10147-012-0447-z.
9. Koie T, Ohyama C, Yamamoto H etal. Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: clinical and oncological outcomes at a single institution. Eur. J. Surg. Oncol. 2012; 38: 1101-1105.
10. Koie T, Suzuki Y, Tobisawa Y etal. Can neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy improve survival in patients with cisplatin-ineligible muscle-invasive bladder cancer? J. Clin. Oncol. 2013; 31 (Suppl): abstr e15565.